+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Influence of body weight, age, and primary tumor site on opioid dose in advanced cancer pain patients



Influence of body weight, age, and primary tumor site on opioid dose in advanced cancer pain patients



Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 44(3): 345-350



The aim of this study was to evaluate the relationship between maximum opioid dose and body weight, age, and primary site in terminal cancer patients in a palliative care unit. Medical records of 152 terminal cancer patients were reviewed retrospectively. Body weight, primary tumor site, age, and analgesic state were used as independent variables, and the maximum opioid dose was used as a dependent variable. There was no correlation between body weight and maximum opioid requirement. Selected independent variables were age and location of the primary lesion in the lower gastrointestinal tract. Maximum opioid dose was negatively correlated with age (P < or =0.0001). Opioid needs of age <65 was 344.2 mg/day oral morphine equivalent, but age 65-74 was 168.5, and age > or =75 was 116.9 mg/day. Elderly cancer patients required a lower amount of opioid analgesia than younger adults. The ratio for age <65, 65-74, and > or =75 was about 1:1/2:1/3.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053839077

Download citation: RISBibTeXText

PMID: 17575439


Related references

Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer. 83(6): 1244-1250,. 15, 1998

The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose. Pain Medicine 4(2): 125-134, 2003

Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition 17(7/8): 590-593 + viii, 2001

Tamoxifen therapy in postmenopausal advanced breast cancer: efficacy at the primary tumor site in 46 evaluable patients. Tumori 67(3): 235-238, 1981

Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning. Palliative Medicine 17(5): 418-422, 2003

Pain, opioid use, and survival in hospitalized patients with advanced cancer. Journal of Clinical Oncology 10(1): 149-155, 1992

Monitoring of opioid therapy in advanced cancer pain patients. Journal of Pain and Symptom Management 13(4): 204-212, 1997

Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering. Pain Medicine 11(11): 1587-1598, 2011

Chiral phosphoric acid-catalyzed asymmetric synthesis of hetero-triarylmethanes from racemic indolyl alcohols. Angewandte Chemie: -, 2018

Prevalence of opioid-related dysuria in patients with advanced cancer having pain. American Journal of Hospice & Palliative Care 28(1): 27-30, 2011

Opioid needs of patients with advanced cancer and the morphine dose-limiting law in Egypt. Journal of Palliative Medicine 14(1): 51-54, 2011

Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?. European Journal of Pain 10(2): 153-159, 2005

In their own words: Seven advanced cancer patients describe their experience with pain and the use of opioid drugs. Journal of Pain and Symptom Management 27(4): 300-309, 2004

Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases. Journal of Pain and Symptom Management 39(5): 930-935, 2010

Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Zhong Xi Yi Jie He Xue Bao 6(1): 77-82, 2008